



Press Release

Cipla appoints Dr. Raju Mistry as Global Chief People Officer

Mumbai, India; April 22, 2019: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") announces the appointment of Dr. Raju Mistry as President and Global Chief People Officer (GCPO) of Cipla.

Raju is an accomplished and veteran Human Resources (HR) leader with over 27 years of global experience across diverse sectors such as Chemicals, Pharma, FMCG, IT, Engineering and Textiles. Prior to joining Cipla, Raju was Chief Human Resources Officer (CHRO) at Jubilant Life Sciences Ltd. For 13 years before that, Raju led the talent, employer brand and leadership programmes of the Aditya Birla Group, and was CHRO of Grasim's Pulp and Fibre business. She has previously worked with Tata Sons, Colgate Palmolive, Siemens, and Mastech Corporation, Canada.

In her role at Cipla, Raju will oversee Human Resources, and Administration and Facilities Management. She will be a member of the Management Council of Cipla, and will report to Umang Vohra, Managing Director & Global Chief Executive Officer.

Commenting on the appointment, Umang Vohra, Managing Director & Global Chief Executive Officer of Cipla said: "We are delighted to welcome Raju to the Cipla family. In the last few years, Cipla has successfully worked towards strengthening its core, reiterating its values and focusing on building a future-ready organisation. Raju brings with her the experience to continue the journey and help us reach new milestones."

About Cipla Limited:

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology and CNS segments are well-known. Our 44 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Dec'18), 3rd largest in the pharma private market in South Africa (IQVIA YTD Dec'18), and is



among the most dispensed generic players in the US. For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on [Twitter](#), [Facebook](#), [LinkedIn](#).

Corporate Communications

Heena Kanal

E-mail: CorpComm@cipla.com

Investor Relations

Naveen Bansal

E-mail: Investor.Relations@cipla.com